Business Context and Reporting Period
This Form 8-K Current Report was filed by NOVAVAX INC on June 24, 2009. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and an increase in the size of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel and governance rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased the number of directors from eight to nine, effective June 24, 2009.
- New Director Appointment: Stanley C. Erck was appointed to the Board of Directors. Mr. Erck previously served as President and CEO of Iomai Corporation and held leadership roles at Procept, Integrated Genetics (Genzyme), and Baxter International.
Compensation and Governance Details
As part of his appointment, Mr. Erck received the following compensation:
- Stock Options: Incentive stock options to purchase 20,000 shares of common stock.
- Exercise Price: $2.44 per share (closing price on June 24, 2009).
- Vesting Schedule: Fully exercisable on December 24, 2009.
- Expiration Date: June 24, 2019.
- Director Compensation: Mr. Erck will be compensated on the same basis as other non-employee directors, as detailed in the Company's most recent proxy statement.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for additional biographical details on Stanley C. Erck.
- Review the Company's most recent proxy statement to confirm the standard compensation package for non-employee directors.
- Confirm the current stock price relative to the $2.44 exercise price granted to the new director.